Evaluation of Ortho VITROS and Roche Elecsys S and NC Immunoassays for SARS-CoV-2 Serosurveillance Applications
暂无分享,去创建一个
B. Biggerstaff | S. Kleinman | N. Thornburg | M. Stone | E. Grebe | D. Bougie | H. Sulaeman | C. Di Germanio | Jefferson M. Jones | H. Dave | Lily McCann | M. Busch | Aditi Sanghavi | Victoria Sclar | Garrick Chatelain
[1] S. O’Brien,et al. Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era , 2022, Microbiology spectrum.
[2] B. Biggerstaff,et al. Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications , 2022, Emerging infectious diseases.
[3] H. Whitaker,et al. Nucleocapsid antibody positivity as a marker of past SARS-CoV-2 infection in population serosurveillance studies: impact of variant, vaccination, and choice of assay cut-off , 2021, medRxiv.
[4] E. Sabino,et al. Intense SARS-CoV-2 transmission among affluent Manaus residents preceded the second wave of the epidemic in Brazil , 2021, The Lancet Global Health.
[5] Noam Brown,et al. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021. , 2021, JAMA.
[6] Marek Orzechowski,et al. SARS‐CoV‐2 antibody persistence in COVID‐19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance , 2021, Transfusion.
[7] S. Kleinman,et al. Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] Marcio K. Oikawa,et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic , 2020, Science.
[9] D. Clifton,et al. Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis , 2020, medRxiv.
[10] R. V. van Lier,et al. Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands , 2020, Nature Communications.
[11] E. Petinaki,et al. Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[12] J. Scott,et al. Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors , 2020, Science.
[13] A. Flahault,et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study , 2020, The Lancet.
[14] David R. Holtgrave,et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York , 2020, Annals of Epidemiology.
[15] Daniel S. Chertow,et al. Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019 , 2020, The Journal of infectious diseases.
[16] Jens K. Boldsen,et al. Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors , 2020, medRxiv.
[17] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .